Diabetes device makers lead the smaller medtechs
Insulin pumps and glucose sensors flew off the shelves, whereas liquid biopsy developers both soared and sank.
Insulet comes out fighting
Pivotal data on its closed-loop insulin delivery system look good, but Medtronic remains a threat.
ADA 2020 – Medtronic leads Insulet, but things could change
Medtronic’s newest closed-loop system posts decent pivotal data, but Insulet and Abbott are waiting in the wings.
Mid cap device makers find rewards in cancer and diabetes
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Led by Tandem, small-cap medtechs pump up the value in 2018
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Typezero takeover puts Dexcom closer to an artificial pancreas
Dexcom can capitalise on its new algorithm technology, but is now enmeshed in a tangled web of partnerships.
